Combined targeting of estrogen receptor alpha and XPO1 prevent AKT activation, remodel metabolic pathways and induce autophagy to overcome tamoxifen resistance

Eylem Kulkoyluoglu-Cotul, Brandi Patrice Smith, Kinga Wrobel, Yiru Chen Zhao, Karen Lee Ann Chen, Kadriye Hieronymi, Ozan Berk Imir, Kevin Duong, Caitlin O’Callaghan, Aditi Mehta, Sunati Sahoo, Barbara B Haley, Hua Chang, Yosef Landesman, Zeynep Madak-Erdogan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A majority of breast cancer specific deaths in women with ERα (+) tumors occur due to metastases that are resistant to endocrine therapy. There is a critical need for novel therapeutic approaches to resensitize recurrent ERα (+) tumors to endocrine therapies. The objective of this study was to elucidate mechanisms of improved effectiveness of combined targeting of ERα and the nuclear transport protein XPO1 in overcoming endocrine resistance. Selinexor (SEL), an XPO1 antagonist, has been evaluated in multiple late stage clinical trials in patients with relapsed and /or refractory hematological and solid tumor malignancies. Our transcriptomics analysis showed that 4-Hydroxytamoxifen (4-OHT), SEL alone or their combination induced differential Akt signalingand metabolism-associated gene expression profiles. Western blot analysis in endocrine resistant cell lines and xenograft models validated differential Akt phosphorylation. Using the Seahorse metabolic profiler, we showed that ERα-XPO1 targeting changed the metabolic phenotype of TAMresistant breast cancer cells from an energetic to a quiescent profile. This finding demonstrated that combined targeting of XPO1 and ERα rewired the metabolic pathways and shut down both glycolytic and mitochondrial pathways that would eventually lead to autophagy. Remodeling metabolic pathways to regenerate new vulnerabilities in endocrine resistant breast tumors is novel, and given the need for better strategies to improve therapy response in relapsed ERα (+) tumors, our findings show great promise for uncovering the role that ERα-XPO1 crosstalk plays in reducing cancer recurrences.

Original languageEnglish (US)
Article number479
JournalCancers
Volume11
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Estrogen Receptor alpha
Autophagy
Tamoxifen
Metabolic Networks and Pathways
Neoplasms
Breast Neoplasms
Smegmamorpha
Endocrine Cells
Cell Nucleus Active Transport
Therapeutics
Nuclear Proteins
Transcriptome
Heterografts
Carrier Proteins
Western Blotting
Phosphorylation
Clinical Trials
Neoplasm Metastasis
Phenotype
Recurrence

Keywords

  • Breast cancer
  • Endocrine resistance
  • ERα
  • Metabolic Rewiring
  • Nuclear transport pathways
  • XPO1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kulkoyluoglu-Cotul, E., Smith, B. P., Wrobel, K., Zhao, Y. C., Chen, K. L. A., Hieronymi, K., ... Madak-Erdogan, Z. (2019). Combined targeting of estrogen receptor alpha and XPO1 prevent AKT activation, remodel metabolic pathways and induce autophagy to overcome tamoxifen resistance. Cancers, 11(4), [479]. https://doi.org/10.3390/cancers11040479

Combined targeting of estrogen receptor alpha and XPO1 prevent AKT activation, remodel metabolic pathways and induce autophagy to overcome tamoxifen resistance. / Kulkoyluoglu-Cotul, Eylem; Smith, Brandi Patrice; Wrobel, Kinga; Zhao, Yiru Chen; Chen, Karen Lee Ann; Hieronymi, Kadriye; Imir, Ozan Berk; Duong, Kevin; O’Callaghan, Caitlin; Mehta, Aditi; Sahoo, Sunati; Haley, Barbara B; Chang, Hua; Landesman, Yosef; Madak-Erdogan, Zeynep.

In: Cancers, Vol. 11, No. 4, 479, 01.04.2019.

Research output: Contribution to journalArticle

Kulkoyluoglu-Cotul, E, Smith, BP, Wrobel, K, Zhao, YC, Chen, KLA, Hieronymi, K, Imir, OB, Duong, K, O’Callaghan, C, Mehta, A, Sahoo, S, Haley, BB, Chang, H, Landesman, Y & Madak-Erdogan, Z 2019, 'Combined targeting of estrogen receptor alpha and XPO1 prevent AKT activation, remodel metabolic pathways and induce autophagy to overcome tamoxifen resistance', Cancers, vol. 11, no. 4, 479. https://doi.org/10.3390/cancers11040479
Kulkoyluoglu-Cotul, Eylem ; Smith, Brandi Patrice ; Wrobel, Kinga ; Zhao, Yiru Chen ; Chen, Karen Lee Ann ; Hieronymi, Kadriye ; Imir, Ozan Berk ; Duong, Kevin ; O’Callaghan, Caitlin ; Mehta, Aditi ; Sahoo, Sunati ; Haley, Barbara B ; Chang, Hua ; Landesman, Yosef ; Madak-Erdogan, Zeynep. / Combined targeting of estrogen receptor alpha and XPO1 prevent AKT activation, remodel metabolic pathways and induce autophagy to overcome tamoxifen resistance. In: Cancers. 2019 ; Vol. 11, No. 4.
@article{53634e45f8034c04a0a7823aaf7d3dda,
title = "Combined targeting of estrogen receptor alpha and XPO1 prevent AKT activation, remodel metabolic pathways and induce autophagy to overcome tamoxifen resistance",
abstract = "A majority of breast cancer specific deaths in women with ERα (+) tumors occur due to metastases that are resistant to endocrine therapy. There is a critical need for novel therapeutic approaches to resensitize recurrent ERα (+) tumors to endocrine therapies. The objective of this study was to elucidate mechanisms of improved effectiveness of combined targeting of ERα and the nuclear transport protein XPO1 in overcoming endocrine resistance. Selinexor (SEL), an XPO1 antagonist, has been evaluated in multiple late stage clinical trials in patients with relapsed and /or refractory hematological and solid tumor malignancies. Our transcriptomics analysis showed that 4-Hydroxytamoxifen (4-OHT), SEL alone or their combination induced differential Akt signalingand metabolism-associated gene expression profiles. Western blot analysis in endocrine resistant cell lines and xenograft models validated differential Akt phosphorylation. Using the Seahorse metabolic profiler, we showed that ERα-XPO1 targeting changed the metabolic phenotype of TAMresistant breast cancer cells from an energetic to a quiescent profile. This finding demonstrated that combined targeting of XPO1 and ERα rewired the metabolic pathways and shut down both glycolytic and mitochondrial pathways that would eventually lead to autophagy. Remodeling metabolic pathways to regenerate new vulnerabilities in endocrine resistant breast tumors is novel, and given the need for better strategies to improve therapy response in relapsed ERα (+) tumors, our findings show great promise for uncovering the role that ERα-XPO1 crosstalk plays in reducing cancer recurrences.",
keywords = "Breast cancer, Endocrine resistance, ERα, Metabolic Rewiring, Nuclear transport pathways, XPO1",
author = "Eylem Kulkoyluoglu-Cotul and Smith, {Brandi Patrice} and Kinga Wrobel and Zhao, {Yiru Chen} and Chen, {Karen Lee Ann} and Kadriye Hieronymi and Imir, {Ozan Berk} and Kevin Duong and Caitlin O’Callaghan and Aditi Mehta and Sunati Sahoo and Haley, {Barbara B} and Hua Chang and Yosef Landesman and Zeynep Madak-Erdogan",
year = "2019",
month = "4",
day = "1",
doi = "10.3390/cancers11040479",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

TY - JOUR

T1 - Combined targeting of estrogen receptor alpha and XPO1 prevent AKT activation, remodel metabolic pathways and induce autophagy to overcome tamoxifen resistance

AU - Kulkoyluoglu-Cotul, Eylem

AU - Smith, Brandi Patrice

AU - Wrobel, Kinga

AU - Zhao, Yiru Chen

AU - Chen, Karen Lee Ann

AU - Hieronymi, Kadriye

AU - Imir, Ozan Berk

AU - Duong, Kevin

AU - O’Callaghan, Caitlin

AU - Mehta, Aditi

AU - Sahoo, Sunati

AU - Haley, Barbara B

AU - Chang, Hua

AU - Landesman, Yosef

AU - Madak-Erdogan, Zeynep

PY - 2019/4/1

Y1 - 2019/4/1

N2 - A majority of breast cancer specific deaths in women with ERα (+) tumors occur due to metastases that are resistant to endocrine therapy. There is a critical need for novel therapeutic approaches to resensitize recurrent ERα (+) tumors to endocrine therapies. The objective of this study was to elucidate mechanisms of improved effectiveness of combined targeting of ERα and the nuclear transport protein XPO1 in overcoming endocrine resistance. Selinexor (SEL), an XPO1 antagonist, has been evaluated in multiple late stage clinical trials in patients with relapsed and /or refractory hematological and solid tumor malignancies. Our transcriptomics analysis showed that 4-Hydroxytamoxifen (4-OHT), SEL alone or their combination induced differential Akt signalingand metabolism-associated gene expression profiles. Western blot analysis in endocrine resistant cell lines and xenograft models validated differential Akt phosphorylation. Using the Seahorse metabolic profiler, we showed that ERα-XPO1 targeting changed the metabolic phenotype of TAMresistant breast cancer cells from an energetic to a quiescent profile. This finding demonstrated that combined targeting of XPO1 and ERα rewired the metabolic pathways and shut down both glycolytic and mitochondrial pathways that would eventually lead to autophagy. Remodeling metabolic pathways to regenerate new vulnerabilities in endocrine resistant breast tumors is novel, and given the need for better strategies to improve therapy response in relapsed ERα (+) tumors, our findings show great promise for uncovering the role that ERα-XPO1 crosstalk plays in reducing cancer recurrences.

AB - A majority of breast cancer specific deaths in women with ERα (+) tumors occur due to metastases that are resistant to endocrine therapy. There is a critical need for novel therapeutic approaches to resensitize recurrent ERα (+) tumors to endocrine therapies. The objective of this study was to elucidate mechanisms of improved effectiveness of combined targeting of ERα and the nuclear transport protein XPO1 in overcoming endocrine resistance. Selinexor (SEL), an XPO1 antagonist, has been evaluated in multiple late stage clinical trials in patients with relapsed and /or refractory hematological and solid tumor malignancies. Our transcriptomics analysis showed that 4-Hydroxytamoxifen (4-OHT), SEL alone or their combination induced differential Akt signalingand metabolism-associated gene expression profiles. Western blot analysis in endocrine resistant cell lines and xenograft models validated differential Akt phosphorylation. Using the Seahorse metabolic profiler, we showed that ERα-XPO1 targeting changed the metabolic phenotype of TAMresistant breast cancer cells from an energetic to a quiescent profile. This finding demonstrated that combined targeting of XPO1 and ERα rewired the metabolic pathways and shut down both glycolytic and mitochondrial pathways that would eventually lead to autophagy. Remodeling metabolic pathways to regenerate new vulnerabilities in endocrine resistant breast tumors is novel, and given the need for better strategies to improve therapy response in relapsed ERα (+) tumors, our findings show great promise for uncovering the role that ERα-XPO1 crosstalk plays in reducing cancer recurrences.

KW - Breast cancer

KW - Endocrine resistance

KW - ERα

KW - Metabolic Rewiring

KW - Nuclear transport pathways

KW - XPO1

UR - http://www.scopus.com/inward/record.url?scp=85065316595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065316595&partnerID=8YFLogxK

U2 - 10.3390/cancers11040479

DO - 10.3390/cancers11040479

M3 - Article

C2 - 30987380

AN - SCOPUS:85065316595

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 4

M1 - 479

ER -